// App-Quantinova.ai

1539 : High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study

Researchers

Presenter

  • Alan J. Kivitz

Principal Investigators

  • Helena Marzo-Ortega

  • Clarence Legerton

  • Joachim Sieper

  • Ricardo Blanco

  • Martin Cohen

  • Evie Maria Delicha

  • Susanne Rohrer

  • Hanno Richards

Medical Centers

  • Altoona Center for Clinical Research, Duncansville, PA

  • Nihr Lmbru, LTHT and LIRMM, UoL, Leeds, United Kingdom

  • Low Country Rheumatology, Articularis Healthcare, Charleston, United States

  • University Clinic Benjamin Franklin, Berlin, Germany

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Montreal University, Montreal, QC, Canada

  • Novartis AG, Basel, Switzerland

Locations

  • United States

  • United Kingdom

  • Germany

  • Spain

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved